Resmed (RSMDF) Capital Expenditures (2009 - 2026)

Resmed (RSMDF) has reported Capital Expenditures for 18 consecutive years, with $51.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 67.16% year-over-year to $51.1 million; the trailing twelve-month figure through Jun 2026 stood at $156.3 million (up 73.91% YoY), and the FY2026 full-year result was $156.3 million, up 73.91% from the prior year.
• Capital Expenditures climbed to $51.1 million in Q2 2026 per RSMDF's latest filing, from $33.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $51.1 million in Q2 2026 and bottomed at $17.8 million in Q3 2024.
• Historically, Capital Expenditures has averaged $30.1 million across 5 years, with a median of $28.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 40.6% in 2024, then surged 140.84% in 2025.
• Over 5 years, Capital Expenditures stood at $27.4 million in 2022, then fell by 14.61% to $23.4 million in 2023, then fell by 11.6% to $20.6 million in 2024, then jumped by 38.24% to $28.5 million in 2025, then surged by 79.15% to $51.1 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $51.1 million, $33.7 million, and $28.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.